Skip to main content
Clinical Trials/ACTRN12616000046404
ACTRN12616000046404
Completed
Phase 4

A multi-centre double-blind randomised controlled trial to determine if a longer duration of amoxicillin-clavulanic acid (compared to shorter duration) improves the short and long term clinical outcomes of children hospitalised with community-acquired pneumonia, in Indigenous children and a developing country

Menzies School of Health Research0 sites324 target enrollmentJanuary 19, 2016

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Pneumonia in children
Sponsor
Menzies School of Health Research
Enrollment
324
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 19, 2016
End Date
June 30, 2022
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\) Hospitalised children aged 3\-mo to \<6\-yrs (in Darwin, children have to be Indigenous)
  • (2\) Have features of severe pneumonia on admission (temperature \>37\.50C or a history of fever at home or observed at the referring clinic, age\-adjusted tachypnoea \[RR\>50 if \<12\-mo; RR\>40 if \>12\-mo] with chest wall recession and/or SpO2 \<92% in air), and consolidation on CXR as diagnosed by treating clinician
  • (3\) After 1\-3 days of IV antibiotics, are afebrile, with improved respiratory symptoms and signs, SpO2 \>90% in air and are ready to be switched to oral amoxicillin\-clavulanate, and
  • (4\) Have symptoms of no longer than 7 days at point of hospitalisation.
  • (5\) Recruited within 24 hours of admission to ward

Exclusion Criteria

  • (1\) Current wheeze
  • (2\) Underlying chronic illness other than asthma (e.g. bronchiectasis, cyanotic congenital heart disease or cardiac failure, neuromuscular disorders, immunodeficiency) that could potentially influence the current illness
  • (3\) Severe malnutrition (weight\-for\-height Z\-score \<\-3\)
  • (4\) Complicated (effusion, empyema or abscess) pneumonia, including tuberculosis
  • (5\) Extra\-pulmonary infection requiring antibiotic therapy (e.g. meningitis)
  • (6\) Beta\-lactam allergy
  • (7\) Previously enrolled
  • (8\) Lack a mobile phone and/or unable to return for follow\-up clinic visits during the next 24 months

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 3
Preventing recurrent acute lower respiratory infections in young Indigenous children using long-term, once-weekly azithromycin: a multicentre randomised controlled trialAcute lower respiratory infection in childrenRespiratory - Other respiratory disorders / diseasesInfection - Other infectious diseases
ACTRN12619000456156Menzies School of Health Research160
Completed
Not Applicable
A double-blind multi-centre randomised controlled trial to investigate the effectiveness of methylprednisolone injections in the treatment of Morton's neuromaMorton's neuromaNervous System DiseasesMononeuropathies of lower limb
ISRCTN13668166Queen Margaret University (UK)150
Not yet recruiting
Phase 2
idocaine (lignocaine) for Neuropathic Cancer Pain – Feasibility study (LiCPain)europathic Cancer Pain
ACTRN12617000747325niversity of Technology Sydney36
Active, not recruiting
Not Applicable
A multicentre, double-blind, randomised controlled trial of sodium bicarbonate to prevent acute kidney injury in patients undergoing cardiopulmonary bypass surgery. - Sodium Bicarbonate StudyCardiac surgical patients in whom the use of cardiopulmonary bypass is planned and having at least one ore more of the following risk factors for post-operative acute kidney injury• Age = 70 years• Preoperative plasma creatinine >120 µmol/L• Heart failure (NYHA class III / IV)• Insulin dependent diabetes mellitus• Valve surgery (with or without coronary artery bypass graft surgery)• Redo cardiac surgery
EUCTR2007-002223-32-IECharité Universitaetsmedizin402
Completed
Not Applicable
A controlled randomised double-blind multicentre study comparing two therapy strategies in disease modifying anti-rheumatic drug-naive early rheumatoid arthritis patients over 48 weeks: induction therapy with adalimumab and methotrexate over 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate monotherapy
ISRCTN36745608Charité - University Medicine Berlin (Germany)180